Bruker Corporation $BRKR Holdings Raised by Polar Asset Management Partners Inc.

Key Points

• Polar Asset Management Partners Inc. significantly increased its stake in Bruker Corporation, acquiring 63,298 shares and raising its ownership by 370.2% during the first quarter, bringing the total to 80,398 shares valued at approximately $3.36 million.
• Bruker Corporation's shares opened at $30.83, with a 52-week range between $28.53 and $72.94, and the company recently reported a quarterly earnings per share (EPS) of $0.32, missing expectations by $0.01.
• The company announced a quarterly dividend of $0.05 per share, reflecting a dividend yield of 0.6%, with the ex-dividend date set for September 23rd.

Polar Asset Management Partners Inc. increased its stake in Bruker Corporation (NASDAQ:BRKR - Free Report) by 370.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 80,398 shares of the medical research company's stock after acquiring an additional 63,298 shares during the period. Polar Asset Management Partners Inc. owned approximately 0.05% of Bruker worth $3,356,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BRKR. Comerica Bank raised its holdings in Bruker by 2.0% in the fourth quarter. Comerica Bank now owns 36,866 shares of the medical research company's stock valued at $2,161,000 after buying an additional 734 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in Bruker in the fourth quarter valued at approximately $249,000. Ameriprise Financial Inc. raised its holdings in Bruker by 10.6% in the fourth quarter. Ameriprise Financial Inc. now owns 1,615,358 shares of the medical research company's stock valued at $94,692,000 after buying an additional 154,768 shares during the period. BNP Paribas Financial Markets raised its holdings in Bruker by 257.3% in the fourth quarter. BNP Paribas Financial Markets now owns 84,758 shares of the medical research company's stock valued at $4,969,000 after buying an additional 61,036 shares during the period. Finally, Captrust Financial Advisors raised its holdings in Bruker by 32.7% in the fourth quarter. Captrust Financial Advisors now owns 5,973 shares of the medical research company's stock valued at $350,000 after buying an additional 1,472 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on BRKR. Wells Fargo & Company cut their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, August 4th. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Barclays dropped their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. Finally, Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Bruker presently has a consensus rating of "Hold" and an average target price of $51.30.

Bruker Stock Performance

Bruker stock traded up $1.48 during mid-day trading on Thursday, reaching $31.97. The company's stock had a trading volume of 1,278,111 shares, compared to its average volume of 2,660,156. The firm has a market cap of $4.85 billion, a price-to-earnings ratio of 61.46, a PEG ratio of 4.33 and a beta of 1.21. The business has a 50 day moving average price of $36.46 and a 200-day moving average price of $39.25. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. Bruker's payout ratio is 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.